Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Quantum Computing Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Quantum Computing Inc trades at $8.64 (market cap $1.96B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.3× Quantum Computing Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | QUBT | |
|---|---|---|
Market Cap | $4.49B | $1.96B |
Sector | Health | Technology |
52-Week High | $28.06 | $24.62 |
52-Week Low | $20.06 | $6.31 |
Enterprise Value | $3.69B | $977.49M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
QUBT trades at $9.37, up 3.54% today, but technical indicators signal a bearish trend with support at $9. The company shows minimal revenue of $682K in 2025 with a net loss of $18.67M, resulting in negative margins. Recent acquisitions and a potential $10M deal with Planck Dynamics highlight growth efforts, but cash burn remains high. Analyst consensus is bullish with a $24 price target, citing commercialization potential in quantum photonics.
The outlook hinges on QUBT's ability to scale revenue and manage cash burn amid intense quantum computing competition. While analyst optimism and policy tailwinds offer upside, high valuation multiples and persistent losses pose significant risks. Investors should weigh the long-term potential against near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
